Paul A Friedman insider trades: Madrigal Pharmaceuticals (MDGL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Paul reports to the SEC
and 5 more companies
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | MDGL | ↓ Sell | 24,520 | $522.39 | $12.8M | Direct | Jan 13, 2026 (4d) |
| Jan 9, 2026 | MDGL | ↓ Sell | 280 | $551.24 | $154K | Direct | Jan 13, 2026 (4d) |
| Dec 10, 2025 | MDGL | ↓ Sell | 24,800 | $552.18 | $13.7M | Direct | Dec 12, 2025 (2d) |
| Aug 13, 2025 | MDGL | ↓ Sell | 129,172 | $370.24 | $47.8M | Direct | Aug 13, 2025 (0d) |
| Aug 12, 2025 | MDGL | ↓ Sell | 46,808 | $355.31 | $16.6M | Direct | Aug 13, 2025 (1d) |
| Jul 18, 2025 | MDGL | ↓ Sell | 1,400 | $350.03 | $490K | Direct | Jul 22, 2025 (4d) |
| Jul 17, 2025 | MDGL | ↓ Sell | 28,876 | $353.19 | $10.2M | Direct | Jul 18, 2025 (1d) |
| Apr 8, 2024 | MDGL | ↓ Sell | 26,270 | $246.19 | $6.5M | Direct | Apr 10, 2024 (2d) |
| Apr 5, 2024 | MDGL | ↓ Sell | 73,730 | $243.93 | $18.0M | Direct | Apr 5, 2024 (0d) |
| Aug 6, 2019 | INCY | ↓ Sell | 100,000 | $82.69 | $8.3M | Direct | Aug 6, 2019 (0d) |
| Nov 20, 2018 | MDGL | ↑ Buy | 4,000 | $117.88 | $472K | Direct | Nov 23, 2018 (3d) |
| Nov 19, 2018 | MDGL | ↑ Buy | 4,000 | $124.00 | $496K | Direct | Nov 19, 2018 (0d) |
| Jun 11, 2018 | MDGL | ↓ Sell | 73,526 | $287.46 | $21.1M | By SQN LLC | Jun 12, 2018 (1d) |
| Nov 16, 2017 | INCY | ↓ Sell | 28,507 | $105.24 | $3.0M | Direct | Nov 20, 2017 (4d) |
| Mar 17, 2017 | INCY | ↓ Sell | 50,000 | $148.72 | $7.4M | Direct | Mar 20, 2017 (3d) |
| Feb 23, 2017 | INCY | ↓ Sell | 50,000 | $120.32 | $6.0M | Direct | Feb 27, 2017 (4d) |
| Nov 18, 2015 | INCY | ↓ Sell | 225,000 | $113.83 | $25.6M | Direct | Nov 19, 2015 (1d) |
| May 27, 2015 | INCY | ↓ Sell | 196,751 | $107.23 | $21.1M | Direct | May 28, 2015 (1d) |
| May 22, 2015 | INCY | ↓ Sell | 102,243 | $108.22 | $11.1M | Direct | May 26, 2015 (4d) |
| Feb 13, 2015 | INCY | ↓ Sell | 120,000 | $74.32 | $8.9M | Direct | Feb 18, 2015 (5d) |
| Dec 24, 2014 | VSTM | ↑ Buy | 3,000 | $8.31 | $25K | Direct | Dec 29, 2014 (5d) |
| Dec 5, 2014 | AUXL | ↓ Sell | 29,689 | $33.73 | $1.0M | Direct | Dec 8, 2014 (3d) |
| Nov 6, 2014 | INCY | ↓ Sell | 185,653 | $67.87 | $12.6M | Direct | Nov 7, 2014 (1d) |
| Feb 20, 2014 | INCY | ↓ Sell | 33,354 | $63.51 | $2.1M | Direct | Feb 21, 2014 (1d) |
| Feb 19, 2014 | INCY | ↓ Sell | 771,182 | $65.65 | $50.6M | Direct | Feb 19, 2014 (0d) |
| Sep 10, 2013 | INCY | ↓ Sell | 376,789 | $37.32 | $14.1M | Direct | Sep 12, 2013 (2d) |
| May 7, 2012 | INCY | ↓ Sell | 225,000 | $22.56 | $5.1M | Direct | May 8, 2012 (1d) |
| Jul 1, 2010 | INCY | ↑ Buy | 10,000 | $10.43 | $104K | Direct | Jul 6, 2010 (5d) |
| Mar 9, 2009 | INCY | ↑ Buy | 20,000 | $2.10 | $42K | Direct | Mar 10, 2009 (1d) |
| Mar 5, 2009 | INCY | ↑ Buy | 20,000 | $2.20 | $44K | Direct | Mar 5, 2009 (0d) |
| Nov 20, 2008 | INCY | ↑ Buy | 13,000 | $2.55 | $33K | Direct | Nov 21, 2008 (1d) |
| Oct 15, 2008 | INCY | ↑ Buy | 10,000 | $4.95 | $50K | Direct | Oct 16, 2008 (1d) |
| Aug 17, 2007 | INCY | ↑ Buy | 16,665 | $5.47 | $91K | Direct | Aug 20, 2007 (3d) |
| Apr 4, 2006 | INCY | ↑ Buy | 5,500 | $3.56 | $20K | Direct | Apr 5, 2006 (1d) |
| Aug 23, 2005 | BOL | ↑ Buy | 630 | $78.85 | $50K | Direct | Aug 24, 2005 (1d) |
| Aug 23, 2005 | INCY | ↑ Buy | 2,700 | $7.24 | $20K | Direct | Aug 23, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MDGL insiders
Open-market trades in the last 12 months
About Paul A Friedman's insider trades
Paul A Friedman is a director at Madrigal Pharmaceuticals (MDGL). Since Aug 23, 2005, Paul has reported 12 open-market purchases worth $1.4M and 24 sales worth $324.3M on SEC Form 4. In the last 12 months: 3 sales ($26.7M).
Their filings also include grants and awards (75 filings), option exercises (28 filings), shares returned to the company (4 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MDGL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.